IMPACC-MEDVAMC

这项补充建议的目的是了解呼吸道疾病的原因，从而改善 诊断和治疗这些常见的、使人衰弱的疾病。免疫表型 新冠肺炎队列研究(IMPACC)中的评估协调了一个全国性的多机构联盟， 收集住院新冠肺炎感染者的详细临床数据和生物样本， 识别与临床病程相关的免疫特征/分子生物标记物的目标，以允许 确定临床干预和决策的优先顺序。本附录支持贝勒学院 Mediced和Michael E.DeBakey VA医疗中心(MEDVAMC)参与IMPACC以促进 住院新冠肺炎患者的筛查和入选。建议的补充研究在以下范围内 家长基金R01 AI135803，中重度哮喘的真菌发病机制。这份副刊是 为临床数据和样本收集/处理的目的而提交，范围将限于 确诊患有新冠肺炎的患者。根据MEDVAMC对新冠肺炎病的预测趋势，我们 预计6个月内可入选多达50名新冠肺炎患者。因为参赛者将被跟踪 到一年，预算延长到18个月。要收集的数据将包括主要数据和次要数据 临床和机械终端以及探索性临床和机械终端。

The objective of this supplement proposal is to understand the causes of airway diseases and thereby improve diagnosis and therapy of these common and debilitating of human ailments. The Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC) study coordinates a national, multi-institution consortium, collecting detailed clinical data and biologic samples from hospitalized COVID-19 infected individuals, with the goal of identifying immune signatures/molecular biomarkers associated with clinical disease course, to allow the prioritization of clinical interventions and decision making. This supplement supports Baylor College of Medicine's and the Michael E. DeBakey VA Medical Center's (MEDVAMC) participation in IMPACC to facilitate screening and enrollment of inpatients with COVID-19. The proposed supplement research is within the scope of parent grant R01 AI135803, Fungal Pathogenesis of Moderate to Severe Asthma. This supplement is submitted for the purpose of Clinical data and sample collection/processing and the scope will be confined to patients confirmed to have COVID-19. Based on projected trends in COVID-19 disease in MEDVAMC, we estimate that up to 50 COVID-19 patients can be enrolled within 6 months. As enrollees will be followed for up to one year, the budget extends to 18 months. Data to be collected will consist of both primary and secondary clinical and mechanistic endpoints as well as exploratory clinical and mechanistic endpoints.